CRBP - Corbus Pharmaceuticals Holdings, Inc.
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Annual
Income Statement
All numbers in thousandsBreakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
35,497
4,822
2,440
1,911
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
81,898
48,614
26,039
15,437
Selling General and Administrative
21,105
12,956
8,964
6,460
Total Operating Expenses
103,003
61,570
35,003
21,896
Operating Income or Loss
-67,505
-56,748
-32,563
-19,985
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
4,005
93
-42
-14
Income Before Tax
-62,179
-55,672
-32,422
-19,999
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-62,179
-55,672
-32,422
-19,999
Net Income
-62,179
-55,672
-32,422
-19,999
Net Income available to common shareholders
-62,179
-55,672
-32,422
-19,999
Reported EPS
Basic
-
-0.98
-0.65
-0.49
Diluted
-
-0.98
-0.65
-0.49
Weighted average shares outstanding
Basic
-
57,000
50,177
41,138
Diluted
-
57,000
50,177
41,138
EBITDA
-
-56,748
-32,563
-19,897